In humans, no efficient treatment exists not only against multifocal liver metastases (LM) but also against recurrent microscopic liver metastases within the liver remnant following curative liver resection. Furthermore, in nonmultifocal LM, partial liver resection could be performed, but in more than 50% of the patients, tumor recurrence within liver remnant is observed, partly due to the growth of dormant cancer cells in the setting of postoperative host immune dysfunction. We investigated the therapeutic potential of interleukin-12 (IL-12) immuno-gene therapies in these experimental models under total vascular exclusion (TVE) of the liver. In rats with multiple LM of DHDK12 colon cancer cells, we observed a significant reduction in tumor volume after retroviral-mediated gene transfer of either herpes simplex virus thymidine kinase (HSV1-TK) and ganciclovir (GCV) administration, or IL-12. Combined treatment with HSV1-TK/GCV and IL-12 resulted in improved tumor volume reduction and even survival. In rats with recurrent microscopic DHDK12 LM established after partial liver resection, we observed significantly decreased recurrent tumor volumes and increased survival after retroviral-mediated IL-12 gene transfer. In both settings, immunohistological analysis revealed that IL-12 immuno-gene therapy was accompanied by an infiltration of CD8 þ T lymphocytes within the tumors. Altogether, our results suggest that IL-12 adjuvant gene therapy could improve the management of patients with either resectable or unresectable LM.
L iver resection is the only treatment known to provide long-term survival and a possible cure in patients with liver metastases (LM) from colorectal cancer. However, the resectability rate does not exceed 25%, being limited by the multiplicity of LM. 1 The results obtained with other therapies, such as systemic or hepatic arterial chemotherapy, radiotherapy, or immunotherapy, still remain disappointing. Therefore, novel therapeutic strategies are needed, of which gene therapy still represents an attractive approach. We and others have previously observed a massive regression of liver tumors in several experimental models, after intratumoral retrovirusmediated transfer of the herpes simplex virus type 1 thymidine kinase (HSV1-TK) gene followed by ganciclovir (GCV) administration. 2, 3 Our results revealed important intratumoral and distant bystander effects, which both appear immune mediated, 3 and mediated by cytokines. 4 Furthermore, we have recently observed that both HSV1-TK, followed by GCV administration, and interleukin-2 (IL-2) retrovirus-mediated gene transfer to the liver through the portal vein under TVE led to a significant antitumoral effect against aggressive macroscopic multiple liver metastases (MLM). 5 In addition, despite complete curative liver resection, recurrent disease develops in nearly two-thirds of patients, most often in the liver remnant. To date, only one study, combining hepatic arterial infusion and systemic chemotherapy, has suggested that adjuvant chemotherapy after liver resection could be helpful for reducing tumor recurrences and increasing survival. 6 There is thus no standard therapeutic approach after liver resection of LM. We and others have postulated that postoperative changes, such as reduction of host cellular immune function and hepatic regeneration following partial liver resection, might stimulate growth of residual microscopic ''dormant LM'' 7 tumor cells within the liver remnant. In this setting, immunotherapy could be a potential treatment by stimulating a systemic antitumor response against residual hepatic tumor cells.
Of all cytokines tested in several experimental tumor models, IL-2 and IL-12 seem to have the strongest antitumor activity. 8 IL-2 is a stronger stimulator of proliferation and cytolytic activity, while IL-12 is a stronger inducer of interferon (IFNg) from natural killer (NK) cells and activated T cells. Furthermore, IL-12 was able to inhibit angiogenesis through the IFN-inducible protein-10. 9 However, despite a substantial antitumor activity, severe toxicity was reported in several clinical trials after systemic administration of IL-2 10, 11 or IL-12.
12
Although not used clinically for colon carcinoma, both IL-2 and IL-12 have been also shown to be effective against experimental colon-derived tumors. 13, 14 In vivo gene therapy is one possible strategy to limit these systemic toxicities by concentrating/targeting cytokine gene expression to a limited area. Whether most experimental strategies using in vivo cytokine gene transfer have targeted tumor cells or not, an alternate approach might be to also deliver the cytokine gene to the regenerating liver 15 as a preventive treatment against recurrences after partial liver resection for LM. 16 In the present study, we used two models of LM in rats, which mimic the two clinical situations in which surgical treatment is not curative, to investigate the potential of IL-12 immuno-gene therapy.
Material and methods

Cell lines and cultures
DHDK12 is a chemically induced rat colon carcinoma cell line from BDIX rats. 17 The tumors generated from these cells never regress spontaneously, contrary to the variant clone REGb, which was not used in this study. The DHDK12 cell line was cultured in a mixture of Dulbecco's modified Eagle's medium (DMEM) and HAM's F10 medium (1:1) containing 10% fetal calf serum FCS.
The M11 cell line 2 was derived from the cCRIP amphotropic retroviral vector packaging cell line, releasing retroviral vectors encoding the HSV1-TK, with a titer of 5 Â 10 5 infectious particles per ml, and was cultured in DMEM containing 10% newborn calf serum. PA317-mIL12 is an amphotrophic packaging cell line releasing retroviral vectors encoding the murine IL-12 (mIL-12) gene, 18 cultured in DMEM containing 10% FCS. The human 1704 packaging cells (Lemoine FM et al, 2004 , in press), derived from embryonic 293 cells producing GALV-pseudotyped retroviral particles harboring a bicistronic Thy1-IRES-HSV1-TK vector, were cultured in DMEM containing 10% FCS.
All cell culture media (GIBCO, Cergy Pontoise, France) were supplemented with 2 mM L-glutamine and penicillin/streptomycin/neomycin (GIBCO). All cell lines were cultured in 5% CO 2 at 371C.
Quantification of cytokine production
The quantification of mIL-12 transgene produced by PA317mIL12 cell line was monitored both in vitro and in vivo by enzyme-linked immunosorbent assays (ELISA) (Becton Dickinson Inc.,. Mountain View, CA). In the culture medium, in vitro, the cytokine produced by PA317mIL12 cell line was 2.9 mg/ml. In vivo, mIL-12 levels were also determined in peripheral blood prior to vector injection, on Days 3 and 5 after vector injection, and on killing.
In vivo experimental protocols
For all experiments, adult BDIX male rats (Iffa Credo, L'arbresle, France), weighting an average of 300 g were used. The care given to the animals and all of the surgical procedures performed was complied with institutional guidelines.
In the first experimental model, a total of 48 rats underwent median laparotomy under ether anesthesia (Day 0). Aggressive nonresectable MLM were induced by direct intraportal vein (IPV) injection of 2 Â 10 7 DHDK12 cells. 5 At Day 10, rats were randomized into four groups. IPV injection and TVE of the liver have been previously reported. PA317mIL12 cells under TVE.
At Day 16, all rats were treated intraperitoneally with 50 mg/kg of GCV twice daily for 7 days. At Day 24, animals of each group were randomly divided into two subgroups at the end of GCV treatment: half of the rats were killed for pathological examination, and the other half were maintained for survival follow-up.
In the second experimental model, a two-third hepatectomy was performed as described by Higgins and Anderson, 19 by resecting the left lateral and median liver lobes. Recurrent microscopic LM were induced through IPV injection within the liver remnant of DHDK12 cells in BDIX rats just after performing 70% hepatectomy. IPV injections were performed using a 30 gauge-catheter (Merck Eurolab, Strasbourg, France). After 24 hours, later the remaining right lateral and caudate liver lobes were isolated from the blood flow and perfused with vector-producing cells. Experimental protocol was as follows:
At Day 0, rats underwent a 70% partial hepatectomy, followed by induction of microscopic recurrent LM through direct IPV injection of 1.5 Â 10 6 DHDK12 cells. At Day 1, rats were randomized into three groups:
In the control group (n ¼ 12), rats were given IPV injections of saline under TVE; in the THY-1 group (n ¼ 12), rats were given IPV injections of 5 Â 10 6 1704 cells under TVE; in the IL-12 group (n ¼ 12), rats were given IPV injections of 5 Â 10 6 PA317mIL12 cells under TVE.
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At Day 24, animals of each group were randomly divided into two subgroups: half of the rats were killed for pathological examinations, and the other half were maintained for survival follow-up.
Pathological examination
Immediately after killing (or spontaneous death), livers were removed, cut into slices, measured, and fixed in 4% paraformaldehyde solution. Specimens were then embedded in paraffin and stained with hematoxylin-eosinsafran (HES). Cancer cells were easily identified based on their morphology. Pathologic examination searched for signs of hepatotoxic lesions characterized by the presence of apoptotic bodies, vacuolated hepatocytes, and marked nuclear changes. Pathological examination of the liver tumors was performed in a blinded fashion. The whole liver was cut into 5-mm slices in order to measure all the tumor volumes. The volume of an individual tumor was measured by determining its smallest and largest diameters on the series of contiguous slices containing the entire tumor, according to the following formula:
on the largest section of the tumor). 20 Immunohistochemical detection of T-cell subsets was performed acccording to the procedure previously described by Whiteland et al, 21 using mouse anti-rat macrophage (ED2), mouse anti-rat CD4 (W3/25), and mouse anti-rat CD8 (MRC OX-8) (Serotec, Oxford, UK) primary antibodies.
Statistical analysis
Tumor volumes from each group were expressed as the mean7standard error. Comparison between mean tumor volumes was performed by Mann and Whitney tests.
Results
In the first experimental model, MLM were generated by direct IPV injection of tumor cells, and we investigated the potential of IL-12 immuno-gene therapy to potentiate suicide gene therapy with HSV1-TK and GCV. 5 Rats were treated at Day 10, a time at which they all showed disseminated LM, the great majority of which developed superficially under Glisson's capsule and had diameters ranging between 1 and 2 mm. They received IPV injection of various retroviral vector-producing cells under TVE, a treatment that we previously showed to be efficient when using suicide gene therapy. At Day 24, half of the treated rats were killed. At macroscopic examination, all rats from the control group presented numerous multifocal macroscopic liver tumors, while there was a clear reduction in tumor number and size in all the treated rats (Fig 1) . Mean tumor volumes were significantly reduced in rats treated with HSV1-TK (3197177 mm These reduced metastatic tumor growths in treated rats translated into an increased median survival (HSV1-TK: 56 days, P ¼ .01; IL-12: 57 days, P ¼ .01; HSV1-TK and IL-12: 62 days, P ¼ .0006) compared to control rats (49 days) (Fig 3) . Furthermore, the rats' median survival, after combined HSV1-TK and IL-12 gene therapies, was significantly longer than after single HSV1-TK gene therapy (P ¼ .01).
Blood mIL-12 could be detected only at 5 days after the portal perfusion under TVE, and was 610 pg/ml (Fig 4) .
On pathological examination of the tumors, animals from control groups showed a typical poorly differentiated adenocarcinoma, consisting mainly of tumor cells organized in lobules or several thick cell cords. There was neither fibrosis nor significant inflammatory cell infiltration. In contrast, after HSV1-TK gene transfer and GCV treatment the stroma of tumors appeared slightly fibrotic and was surrounded by a few mononuclear inflammatory cells. After combined gene therapy, tumors were essentially scars with fibrosis and voluminous macrophagic infiltration in the portal spaces. There were few remaining cancer cells that were poorly organized and often necrotic. Immunohistochemical detection of T-cell subsets showed a rare infiltration by CD4 þ and CD8 þ cells in control rats. Interestingly, there was a dramatic tumor infiltration by CD8 þ T cells in the rat treated by combined gene therapy. Furthermore, after IL-12 gene transfer, CD8 þ T cells were localized not only at the periphery of the tumors but also in the stroma of the tumors (Fig 5) . Neither macroscopic (i.e. liver necrosis, liver abscess) nor microscopic signs (i.e. apoptotic cell and vacuolation of hepatocytes) of liver toxicity were noted in treated rats.
In the second experimental model, we generated recurrent microscopic LM by direct IPV injections of 1.5 Â 10 6 DHDK12 cells just after performing 70% hepatectomy. We hypothesized that interleukin-12 (IL-12) gene transfer would elicit an immune response that could prevent growth of microscopic recurrent LM within the liver remnant after partial liver resection.
Rats were killed at Day 24, a time at which they all showed recurrent macroscopic LM, the great majority of which developed within the liver remnant (Fig 6) . Mean tumor volumes were similar in the control and gene marker groups (186754 vs 179779 mm 3 ). IL-12 gene therapy led to a significant reduction in tumor volumes (19713 mm 3 , P ¼ .007) (Fig 7) . Median survival was not different between the control and gene marker groups (Fig 8) . However, a significant increased median survival was observed after IL-12 gene transfer compared to both control and gene marker groups (47 vs 59 days, P ¼ .0007). Blood mIL-12 could be 
IL-12 adjuvant gene therapy for liver metastases A Alves et al
detected only at 5 days after the portal perfusion under TVE, and was 500 pg/ml (Fig 9) .
On pathological examination of the tumors, animals of control and gene marker groups showed typical recurrent poorly differentiated adenocarcinoma. Few remaining cancer cells were observed after IL-12 gene therapy. These cells were poorly organized, often necrotic, and located in a dense fibrotic reaction surrounded by inflammatory mononuclear cells. Inflammatory reaction with macrophages was observed at the periphery of the tumors in treated animals. There was a dramatic tumor infiltration by CD8 þ T cells in the rat treated by IL-12 gene therapy, not only at the periphery of the tumors but also in the stroma of the tumors (Fig 10) . Neither macroscopic (i.e. liver necrosis, liver abscess) nor microscopic signs (i.e. apoptotic cell and vacuolation of hepatocytes) of liver toxicity were noted in treated rats.
Discussion
In both preclinical rat models of LM, we have observed that IL-12 gene transfer can induce not only a significant antitumoral effect against established MLM but also an efficient prevention of microscopic cancer cells growth after partial liver resection that lead to a significantly prolonged survival.
In the first part of the experiment, we have evaluated the therapeutic efficacy of IL-12 gene transfer and the possibility of a synergistic effect with HSV1-TK suicide gene, using our locoregional procedures of gene delivery.
We have recently reported that TVE of the liver led to a high specificity of gene targeting within LM, without toxicity in the extratumoral parenchyma. 5 Our choice of using IL-12 is due to its central role in the immune system; IL-12 appears as one of the most potent cytokines for stimulating antitumor immunity, 22, 23 acting by the: (i) induction of a TH1 immune response, (ii) activation of natural killer cells and cytotoxic T lymphocytes, (iii) enhanced expression of adhesion molecules of endothelial cells, thus facilitating the traffic of lymphocytes to the tumor, and (iv) induction of a potent antiangiogenic effect. Strong antitumoral activity of IL-12 has been demonstrated in several tumor models, including liver tumors. [23] [24] [25] Furthermore, after intratumoral injection of adenovirus expressing IL-12, complete liver tumor regression has been observed in nearly one-third of animals, 13, 26 leading to significantly increased survival.
However, most of these studies involved direct intratumoral injection of the vector, a strategy that is not feasible for diffuse MLM. As a matter of fact, very few studies have been devoted to evaluate gene therapy in preclinical models of liver tumors. Barajas et al 27 have recently reported that adenovirus-mediated delivery of IL-12 given by intrahepatic arterial route was efficient in the treatment of a very aggressive model of multifocal HCC in rats, with two out of 10 rats experiencing complete tumor regression. Our results showed in an aggressive model of nonresectable MLM that retroviral vectors expressing IL-12 gene significantly reduced tumor volume and that combination of IL-12 and HSV1-TK gene transfer was more effective than therapy with either These results compared favorably with our previous results with HSV1-TK gene combined with IL-2 gene therapy. 5 The synergistic effect of IL-12 and HSV1-TK genes observed in the present study could be explained by the association of two antitumoral mechanisms: first, direct cytotoxic effect by HSV1-TK gene transfer and GCV treatment and, second, strong induction of IFNg from NK cells and activated T cells, associated with probable inhibition of tumor angiogenesis as previously suggested. 9 However, this antitumoral efficiency delayed but did not prevent tumor recurrence and subsequent death. The low efficacy of In the second part of the study, we used a preclinical model mimicking recurrent microscopic LM after a curative partial hepatectomy. We have previously reported that portal perfusion under TVE of retroviruses 24 hours after a two-thirds hepatectomy led to an expression of the recombinant provirus in up to 5% of the hepatocytes. 15 No recombinant provirus could be detected by polymerase chain reaction in other tissues, including spleen, lung, kidney, and brain. In this setting, we chose not to use HSV1-TK gene transfer due to the risk of toxic hepatitis. Previous studies have reported liver damage after HSV1-TK/GCV gene therapy system leading to high mortality. [28] [29] [30] This liver toxicity was due to adenoviral vectors that are able to infect efficiently a large variety of nondividing cells. We thus explored the adjuvant effect of IL-12 immuno-gene therapy. We observed elevated serum IL-12 levels without systemic toxicity, showing the efficiency of gene transfer and suggesting a high local production of IL-12. This led to a significant reduction of recurrent microscopic LM and a significant increase in survival. Pathological examination showed inflammatory reaction with macrophages observed at the periphery of the tumors in treated animals. Immunohistochemical detection of T-cell subsets showed a dramatic tumor infiltration by CD8 þ T cells in rats treated by IL-12 gene therapy. Furthermore, NKT cells were also observed around and in the liver tumor. These results suggest that the IL-12 secreted locally induced infiltration of NKT cells and cytotoxic T cells in the tumor site, leading to tumor regression. We did not study the mechanism of antiangiogenesis contributing to tumor regression induced by gene transfer of IL-12 to the liver. However, the two effects including NK activation and antiangiogenesis may in fact be closely related. A recent study shows that NK cells are required mediators of angiogenesis inhibition by IL-12 suggesting that cytotoxic damage of endothelial cells by NK cells is a potential mechanism by which IL-12 can suppress neovascularization. 31 Our results are in agreement with those of Jarnagin et al 16 who recently reported that herpes simplex virusmediated IL-12 gene reduced the growth of residual microscopic cancer at the time of parental liver tumor surgery. However, in this model, residual microscopic cancer was induced by intrasplenic injection of cancer cells followed by a splenectomy that might impact the host immune system. Although they observed at 3 weeks a significant reduction of recurrent liver tumors, the authors did not follow the animals over a long term.
In summary, our results suggest that IL-12 adjuvant gene therapy could stimulate antitumor response in humans with both resectable and unresectable LM. 
